Kodama, Hiroaki
Wakuda, Kazushige
Yabe, Michitoshi
Nishioka, Naoya
Miyawaki, Eriko
Miyawaki, Taichi
Mamesaya, Nobuaki
Kawamura, Takahisa
Kobayashi, Haruki
Omori, Shota
Ono, Akira
Kenmotsu, Hirotsugu
Naito, Tateaki
Murakami, Haruyasu
Endo, Masahiro
Takahashi, Toshiaki
Article History
Received: 30 July 2020
Accepted: 15 September 2020
First Online: 21 September 2020
Compliance with ethical standards
:
: K. Wakuda reports grants and personal fees from AstraZeneca and Chugai Pharmaceutical Co., Ltd.; personal fees from Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly K.K., Ono Pharmaceutical, and MSD; and grants from Novartis and AbbVie, all outside the submitted work. S. Omori reports grants from Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical, AstraZeneca K.K., Boehringer Ingelheim, Taiho Pharmaceutical, and MSD K.K., all outside the submitted work. H. Kobayashi reports grants from Eli Lilly K.K and Taiho Pharmaceutical, both outside the submitted work. A. Ono reports grants from Taiho Pharmaceutical, Ono Pharmaceutical, Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K.K., all outside the submitted work. H. Kenmotsu reports grants and personal fees from AstraZeneca KK, Pfizer Japan, Inc., Chugai Pharmaceutical Co., Ltd., and Boehringer Ingelheim and grants from Kyowa Hakko Kirin Co., Ltd., Novartis Pharma K.K., Daiichi Sankyo Co., Ltd., Pfizer K.K., Eli Lilly K.K, Bristol-Myers Squibb, Ono Pharmaceutical Co, Ltd., and MSD K.K., all outside the submitted work. T. Naito reports grants from Ono Pharmaceutical Co., Ltd., Pfizer US, Inc., and Mochida Pharmaceutical Co., Ltd., all outside the submitted work. H. Murakami reports grants and personal fees from AstraZeneca KK, Pfizer Japan, Inc., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., and Taiho Pharmaceutical; grants from AbbVie, Daiichi Sankyo, and IQvia; and personal fees from Bristol-Myers Squibb Japan, Ono Pharmaceutical, and MSD K.K., all outside the submitted work. M. Endo reports personal fees from AstraZeneca Co., outside the submitted work. T. Takahashi reports grants and personal fees from AstraZeneca KK, Pfizer Japan, Inc., Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Boehringer Ingelheim Japan, Inc., and Pfizer Japan, Inc. and personal fees from Roche Diagnostics K.K., all outside the submitted work. The remaining authors have not conflicts of interest to declare.
: All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by the Clinical Research Ethics Committee of Shizuoka Cancer Center Hospital and Research Institute.
: The ethics review board of Shizuoka Cancer Center approved the present study and permitted the use of the opt-out method in lieu of written informed consent.
: Not applicable.
: Not applicable.